# Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia

> **NCT06072040** · PHASE1,PHASE2 · TERMINATED · sponsor: **Auregen Biotherapeutics, SA** · enrollment: 3 (actual)

## Conditions studied

- Microtia

## Interventions

- **COMBINATION_PRODUCT:** AUR-201

## Key facts

- **NCT ID:** NCT06072040
- **Lead sponsor:** Auregen Biotherapeutics, SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-01-26
- **Primary completion:** 2025-11-14
- **Final completion:** 2025-11-14
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06072040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06072040, "Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06072040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*